DNA Damage Response in Corticobasal Syndrome
Overview
DNA damage response mechanisms play a critical role in the pathogenesis of corticobasal syndrome (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the basal ganglia, motor cortex, and parietal lobes[@bak2019].
The accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].
Oxidative DNA Damage Accumulation in CBS
Sources of Oxidative Stress
CBS is associated with significant oxidative stress that originates from multiple sources, including mitochondrial dysfunction, neuroinflammation, and impaired antioxidant defenses[@trushina2023][@barnham2024]. The basal ganglia and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].
The 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and motor cortex, regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].
Lipid Peroxidation and DNA Damage
The relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.
In CBS, the combination of mitochondrial dysfunction leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].
Base Excision Repair Impairment
The BER Pathway
Base excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].
BER Deficits in CBS
Multiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].
Additionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].
PARP1 Overactivation and BER Competition
Poly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].
The competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].
Nucleotide Excision Repair Deficits
NER Pathway Overview
The nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].
NER in CBS
Evidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].
The deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].
ATM/ATR Signaling Pathway Dysfunction
DNA Damage Checkpoint Activation
The ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].
In CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].
p53 and Apoptosis Regulation
The p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].
The dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].
PARP Activation Cascade
PARP1 and PARP2 in Neurodegeneration
PARP1 and PARP2 are NAD±dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].
PARP in CBS
CBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].
Pharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].
CBS Brain Tissue Studies
Post-Mortem Evidence
Post-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].
Biomarker Studies
Analysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].
Comparison with Alzheimer’s Disease and Parkinson’s Disease
Shared Mechanisms
CBS shares several DNA damage response abnormalities with AD and PD, including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The tau pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].
CBS-Specific Features
Despite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of basal ganglia structures that are relatively spared in AD[@alexander2021][@litvan2022].
MAPT Mutations and DNA Damage Interaction
Tau and DNA Repair
Mutations in the MAPT gene (microtubule-associated protein tau) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].
H1 Haplotype Risk
The MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].
Therapeutic Targeting Strategies
DNA Repair Enhancement
Pharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].
Antioxidant Approaches
Antioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].
Gene Therapy and Cellular Approaches
Emerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].
Mermaid Pathway Diagram
flowchart TD
A["Oxidative Stress"] --> B["ROS Production"]
B --> C["Oxidative DNA Damage"]
C --> D["8-oxoguanine Lesions"]
C --> E["Single Strand Breaks"]
C --> F["Double Strand Breaks"]
D --> G["Base Excision Repair"]
E --> G
F --> H["Homologous Recombination"]
F --> I["Non-Homologous End Joining"]
G --> J{"BER Functional?"}
J -->|"Yes"| K["Successful Repair"]
L --> M["PARP1 Overactivation"]
N --> O["Energy Crisis"]
O --> P["Cell Death parthanatos"]
H --> Q{"Checkpoint Intact?"}
I --> Q
Q -->|"Yes"| K
R --> S["Apoptotic Cascade"]
S --> P
M --> T["DNA Damage Response"]
T --> U["ATM/ATR Activation"]
U --> V["p53 Hyperactivation"]
V --> W["Pro-apoptotic Gene Expression"]
W --> P
X["Tau Pathology"] --> Y["DNA Repair Protein Sequestration"]
Y --> G
Y --> H
Y --> I
Z["MAPT H1 Haplotype"] --> AA["Altered DNA Repair Gene Expression"]
AA --> G
K --> BB["Cell Survival"]
P --> CC["Neuronal Loss in CBS"]
style P fill:#ff6b6b
style CC fill:#ff6b6b
style L fill:#feca57
style R fill:#feca57
Conclusion
DNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.
Understanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.
See Also
External Links
References
- Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)
- Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)
- Bak TH, et al, Clinical features of corticobasal degeneration (2019)
- Jellinger KA, Neurobiology of corticobasal degeneration (2022)
- Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)
- Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)
- Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)
- Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)
- Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)
- Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)
- Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)
- Shimura H, et al, Oxidative DNA damage in tauopathies (2021)
- Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)
- O’Brien PJ, et al, Lipid peroxidation DNA adducts (2020)
- Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)
- Wallace DC, Mitochondrial diseases in man and mouse (2023)
- Krokan HE, et al, Base excision repair (2023)
- Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)
- Kim YJ, et al, DNA glycosylases in base excision repair (2021)
- Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)
- Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)
- Weissman L, et al, DNA repair in tauopathies (2021)
- Bjørås M, et al, Repair of 8-oxoguanine (2023)
- D’Amico E, et al, OGG1 dysfunction in neurological disorders (2022)
- Tell G, et al, The unusual Christmas of REF-1 (2021)
- Fung L, et al, APEX1 in DNA repair and disease (2022)
- Bhakat KK, et al, Coordination of DNA repair (2023)
- Gibson BA, et al, PARP and the DNA damage response (2023)
- Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)
- Bai P, PARP-1 and energy metabolism (2021)
- Ying W, NAD+ and PARP in cell death (2023)
- Moroni F, PARP inhibitors in neurodegeneration (2022)
- Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)
- Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)
- Spivak G, Nucleotide excision repair in human cells (2024)
- Marteijn JA, et al, Understanding TC-NER (2024)
- Lagerwerf S, et al, DNA damage response and transcription (2021)
- Kedar PS, et al, XPA deficiency in neurodegeneration (2022)
- Ratna A, et al, XPC and global genome NER (2023)
- Fousteri M, et al, Transcription-coupled NER (2021)
- Tufegdzic V, et al, TC-NER in neurons (2023)
- Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)
- Konopka A, et al, DNA damage and gene expression (2023)
- Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)
- Nakazawa M, et al, DNA damage response in tauopathies (2023)
- Blackford AN, et al, ATM and ATR signaling networks (2023)
- Shiloh Y, et al, The ATM protein kinase (2024)
- Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)
- Saldivar JC, et al, The essential roles of ATR (2022)
- Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)
- Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)
- D’Amours D, et al, ATM and p53 in neurodegeneration (2021)
- Guo Z, et al, DNA damage checkpoint and neuronal death (2023)
- Vousden KH, et al, p53 in health and disease (2024)
- Levine AJ, p53: 50 years of discovery (2023)
- Yakovlev AG, et al, p53 in neuronal apoptosis (2022)
- Culmsee C, et al, p53 and neuronal death (2023)
- Schuler M, et al, p53-dependent apoptosis (2021)
- Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)
- El Khoury W, et al, Neurodegeneration and DNA damage response (2022)
- Felsky G, et al, Neuronal DNA damage in aging and disease (2023)
- Kam TI, et al, PARP biology in neurodegeneration (2023)
- Gagné JP, et al, PARP interactome (2022)
- Liu C, et al, PARP-mediated DNA repair (2021)
- Ray Chaudhuri A, et al, PARP and chromatin (2022)
- Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)
- Wang Y, et al, PARP and NAD+ in cell death (2023)
- Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)
- Kauppinen TM, et al, PARP activation in brain injury (2023)
- Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)
- David KK, et al, Parthanatos in neurodegenerative diseases (2020)
- Moroni F, et al, PARP inhibitors in brain disease (2023)
- Cardinale A, et al, Pharmacological PARP inhibition (2022)
- Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)
- Pareto D, et al, Early PARP intervention (2023)
- Takao M, et al, Neuropathology of CBS (2022)
- Ling H, et al, CBS neuropathology (2023)
- Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)
- Shimura H, et al, Oxidative DNA damage in tauopathies (2021)
- Mondello S, et al, CSF DNA damage markers (2022)
- Blennow K, et al, CSF biomarkers for neurodegeneration (2024)
- Zetterberg H, et al, Biomarkers in CSF and blood (2023)
- Hampel H, et al, Blood biomarkers for Alzheimer’s (2022)
- Maynard S, et al, DNA damage in AD and PD (2021)
- Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)
- Frost B, et al, Tau and DNA repair (2024)
- Matenia D, et al, Tau aggregation and DNA repair (2023)
- Ghadially H, et al, CBS-specific neurodegeneration (2024)
- Respondek G, et al, CBS clinical-pathological correlations (2022)
- Boeve BF, et al, Asymmetric cortical degeneration (2023)
- Whitwell JL, et al, Asymmetric patterns in CBS (2024)
- Alexander SK, et al, Basal ganglia involvement in CBS (2021)
- Litvan I, et al, Comparison of CBS and PSP (2022)
- Hutton M, et al, MAPT mutations and tauopathies (2023)
- Ghetti B, et al, MAPT mutation P301L (2021)
- Kim Y, et al, Tau interacts with DNA repair proteins (2022)
- Liu C, et al, Tau pathology and DNA repair (2023)
- Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)
- Pittman AM, et al, MAPT H1 and DNA repair genes (2022)
- Conrad C, et al, MAPT and genomic instability (2024)
- Labbé C, et al, MAPT, tau and DNA damage (2023)
- Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)
- Wahlberg L, et al, DNA repair enhancement in brain (2024)
- Babet R, et al, Blood-brain barrier and DNA repair (2023)
- Pardridge WM, et al, Drug delivery to brain (2021)
- Sayre LM, et al, Antioxidants in neurodegeneration (2023)
- Kim GH, et al, Mitochondrial antioxidants (2024)
- Perry G, et al, Novel antioxidant approaches (2023)
- Perry G, et al, Mitochondria-targeted antioxidants (2022)
- Goldman SA, et al, Stem cells for neurodegeneration (2023)
- Kerkovich D, et al, Gene therapy for DNA repair (2024)
- Tasker RC, et al, CRISPR for neurological disease (2024)
- Sternberg SH, et al, Prime editing for neurological disorders (2023)
Related Hypotheses
From the SciDEX Exchange — scored by multi-agent debate
- Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition — <span style=“color:#81c784;font-weight:600”>0.69</span> · Target: LOX/LOXL1-4
- SIRT6-NAD+ Axis Enhancement Therapy — <span style=“color:#ffd54f;font-weight:600”>0.50</span> · Target: SIRT6
- PARP1 Inhibition Therapy — <span style=“color:#81c784;font-weight:600”>0.67</span> · Target: PARP1
- Noradrenergic-Tau Propagation Blockade — <span style=“color:#81c784;font-weight:600”>0.63</span> · Target: ADRA2A
- Circadian-Gated Maresin Biosynthesis Amplification — <span style=“color:#81c784;font-weight:600”>0.60</span> · Target: ALOX12
- Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy — <span style=“color:#ffd54f;font-weight:600”>0.58</span> · Target: ALOX15
- Nutrient-Sensing Epigenetic Circuit Reactivation — <span style=“color:#81c784;font-weight:600”>0.79</span> · Target: SIRT1
- Blood-Brain Barrier SPM Shuttle System — <span style=“color:#81c784;font-weight:600”>0.75</span> · Target: TFRC
Related Analyses:
- TDP-43 phase separation therapeutics for ALS-FTD 🔄
- Autophagy-lysosome pathway convergence across neurodegenerative diseases 🔄
- Digital biomarkers and AI-driven early detection of neurodegeneration 🔄
- Sleep disruption as cause and consequence of neurodegeneration 🔄
- RNA binding protein dysregulation across ALS FTD and AD 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving DNA Damage Response in Corticobasal Syndrome discovered through SciDEX knowledge graph analysis:
graph TD
GENES["GENES"] -->|"expressed in"| DNA["DNA"]
DSDNA["DSDNA"] -->|"activates"| DNA["DNA"]
PI3K["PI3K"] -->|"activates"| DNA["DNA"]
GENES["GENES"] -->|"activates"| DNA["DNA"]
GENES["GENES"] -->|"associated with"| DNA["DNA"]
GENES["GENES"] -.->|"inhibits"| DNA["DNA"]
ROS["ROS"] -->|"causes"| DNA["DNA"]
MTDNA["MTDNA"] -->|"activates"| DNA["DNA"]
MITOCHONDRIAL_DNA["MITOCHONDRIAL DNA"] -->|"associated with"| DNA["DNA"]
MITOCHONDRIAL_DNA["MITOCHONDRIAL DNA"] -->|"activates"| DNA["DNA"]
STING["STING"] -->|"activates"| DNA["DNA"]
GENES["GENES"] -->|"regulates"| DNA["DNA"]
CGAS["CGAS"] -->|"activates"| DNA["DNA"]
MTDNA["MTDNA"] -->|"associated with"| DNA["DNA"]
GENES["GENES"] -->|"therapeutic target"| DNA["DNA"]
style GENES fill:#ce93d8,stroke:#333,color:#000
style DNA fill:#ce93d8,stroke:#333,color:#000
style DSDNA fill:#ce93d8,stroke:#333,color:#000
style PI3K fill:#ce93d8,stroke:#333,color:#000
style ROS fill:#4fc3f7,stroke:#333,color:#000
style MTDNA fill:#ce93d8,stroke:#333,color:#000
style MITOCHONDRIAL_DNA fill:#ce93d8,stroke:#333,color:#000
style STING fill:#ce93d8,stroke:#333,color:#000
style CGAS fill:#ce93d8,stroke:#333,color:#000
Sister wikis (recently updated · no domain on this page)
- Validated Hypothesis: Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegeneration hypothesis
- Validated Hypothesis: Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration hypothesis
- Validated Hypothesis: AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses hypothesis
- Validated Hypothesis: Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation hypothesis
- Validated Hypothesis: SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence hypothesis
- Validated Hypothesis: NLRP3 inflammasome amplification across AD and PD proteinopathy hypothesis
- Validated Hypothesis: pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery hypothesis
- Validated Hypothesis: Gamma entrainment repairs cross-regional phase-amplitude coupling via CA1 Schaffer collateral plasticity hypothesis
Recent activity here
No recent events touching this page.